POTENTOX


A patent protected novel antibiotic adjuvant entity that works in Multi drug resistant gram negative pathogens especially in Aminoglycoside and Quinolone resistance where other drugs fail to respond

Potentox Features

Potentox inhibits bacterial growth by dual mechanism of inhibiting cell wall synthesis and simultaneously blocking protein synthesis, thus preventing further production of bacterial cell wall proteins.

Potentox also inhibits the super coiling activity of DNA gyrase thereby making it susceptible to quinolone resistant strains.

Breaks bacterial resistance cycle by breaking and preventing biofilm formation.

Indications

  • Lower respiratory tract infections (LRTI)
  • Skin and skin structure infections
  • Intrabdominal infections
  • Bone and joint infections
  • Diabetic patients undergoing surgeries for prophylaxis and in other post operative prophylaxis cases

Product Presentation

0.625, 1.25 or 2.5 g dry powder for injection

Patent Granted

India Patent No. 235775
US Patent No. 8178501
EU Patent No. 1861110

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to VRL India, its subsidiaries or affiliates. No use of any VRL India trademark, trade name, or trade dress in this site may be made without the prior written authorization of VRL India, except to identify the product or services of the company.

Back to Top